← Leaderboards
Richard August Shimkets
Abeome Corporation
$2,000,454
Attributed
$2,000,454
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $809.6K · FY2013–17$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$2,000,454 · 3
By mechanism
R44$1,482,472 · 1
R43$517,982 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Transgenic Mice”
- Alan F Horwitz · University Of Virginia Charlottesville$34,297,512
- Len Alexander Pennacchio · University Of Calif-Lawrenc Berkeley Lab$31,596,948
- Stephen M Strittmatter · Yale University$29,110,810
- David Heimbrook · Leidos Biomedical Research, Inc.$28,837,662
- Lennart Mucke · Scripps Research Institute$28,581,678
- Stanley B Prusiner · University Of California San Francisco$28,330,751
Research focus
Transgenic MiceProteinsPublic Health RelevanceTechnologyNeutralizing AntibodyPharmacologic SubstanceMonoclonal AntibodiesHypercholesterolemiaResponseInjection Of Therapeutic AgentMouse ModelAnimalsAntibody RepertoireNovel Therapeutic InterventionAntigensDiagnosticAntibodiesHybridomasEscherichia ColiAffinityBiotechnologyImmune SystemAntibody-Producing CellsEvaluation
Grant awards (4)
Novel Therapeutic Approach to Hypercholesterolemia Using Anti-PCSK9 Selected Immune Repertoires$672,880
R44 · FY2017 · HL · contact PI
Novel Therapeutic Approach to Hypercholesterolemia Using Anti-PCSK9 Selected Immune Repertoires$809,592
R44 · FY2016 · HL · contact PI
Novel Therapeutic Approach to Hypercholesterolemia Using Next-Generation DNA Sequ$242,066
R43 · FY2014 · HL · contact PI
Semi-targeted Immuno-Therapeutic Approach for Treatment of Obesity$275,916
R43 · FY2013 · DK · contact PI